Dive Brief:

潜水简介：

Triveni Bio has raised $115 million in Series B funding, the company said Wednesday, adding to an upward trend in investment this year in startups developing drugs for immune conditions.

Triveni Bio周三表示，该公司已筹集到1.15亿美元的B系列资金，这增加了今年对开发免疫疾病药物的初创公司的投资上升趋势。

The Watertown, Massachusetts-based biotech will use the funds to develop a pipeline of antibody drugs for inflammatory diseases. Its most advanced prospect, codenamed TRIV-509, is in development for atopic dermatitis. Triveni aims to ask the Food and Drug Administration early next year to begin its first trial.  .

总部位于马萨诸塞州沃特敦的生物技术公司将利用这笔资金开发一条用于治疗炎症性疾病的抗体药物管道。其最先进的前景，代号为TRIV-509，正在开发特应性皮炎。特里韦尼计划在明年年初要求食品和药物管理局开始其首次试验。。

Goldman Sachs Alternatives led the new funding, which follows a $92 million Series A the company secured last year. It’s at least the 11th venture financing of $100 million or more for an immune drug developer in 2024, more than doubling 2023’s total, according to data compiled by BioPharma Dive.

。根据BioPharma Dive汇编的数据，这是2024年免疫药物开发人员第11次获得1亿美元或以上的风险融资，是2023年总额的两倍多。

Dive Insight:

潜水洞察：

Like many other immunology startups to come along recently, Triveni is taking a targeted approach to drug discovery. The company is using troves of genetic data and what it claims to be “best-in-class antibody design” to create medicines it believes will be differentiated from others in development. .

像最近出现的许多其他免疫学初创公司一样，Triveni正在采取有针对性的药物发现方法。该公司正在利用大量的基因数据和它声称的“同类最佳抗体设计”来制造它认为在开发过程中会与其他药物有所区别的药物。。

Triveni faces stiff competition. Its lead program is in atopic dermatitis, a common form of eczema and the target of a number of effective, approved therapies, among them Sanofi and Regeneron Pharmaceuticals’ fast-selling Dupixent. Several would-be competitors are much further along in clinical testing than Triveni, too. .

特里韦尼面临着激烈的竞争。它的主要项目是特应性皮炎，这是湿疹的一种常见形式，也是许多有效且经批准的疗法的目标，其中包括赛诺菲和Regeneron Pharmaceuticals的畅销Dupixent。一些潜在的竞争对手在临床测试方面也比Triveni走得更远。。

“There's obviously been progress made, from where they were even five or 10 years ago,” said CEO Vishal Patel, in an interview. “But there's a lot of room to do better, help patients with efficacy, choice and convenience.”

首席执行官维沙尔·帕特尔（VishalPatel）在接受采访时表示：“与五年或十年前相比，显然取得了进展。”。“但还有很大的改进空间，可以帮助患者获得疗效、选择和便利。”

Triveni, which launched last year out of a merger between two biotech startups, thinks it can help fill that gap. Some people don’t respond to available atopic dermatitis therapies. And a lot of those drugs “are really targeting inflammation, said Jennifer Dovey, the company’s chief scientific officer, but the disease’s “vicious cycle consists of [skin] barrier dysfunction, inflammation and itch.”  .

特里韦尼（Triveni）去年在两家生物技术初创公司的合并中成立，他认为这有助于填补这一空白。有些人对现有的特应性皮炎疗法没有反应。。

Triveni says TRIV-509 might be able to impact all three aspects. The drug targets two enzymes known as kallikreins 5 and 7, which are overexpressed in the majority of people with atopic dermatitis, according to Dovey. In a statement Wednesday, the company said preclinical research has suggested its approach might be a more potent way of targeting the disease than drugs aimed at the cytokine IL-4R, like Dupixent.

特里韦尼说，TRIV-509可能会影响所有三个方面。Dovey说，该药物靶向两种酶，即激肽释放酶5和7，它们在大多数特应性皮炎患者中过表达。在周三的一份声明中，该公司表示，临床前研究表明，与针对细胞因子IL-4R的药物（如Dupixent）相比，其方法可能是一种更有效的靶向疾病的方法。

.

.

Triveni is also working on a bispecific antibody that acts on kallikreins 5 and 7 as well as a cytokine, IL-13, that’s involved in inflammation. It hasn’t said which diseases that drug will treat. A third candidate is in development for a type of hereditary pancreatitis that affects about 10,000 people in the U.S.

Triveni还在研究一种双特异性抗体，该抗体作用于激肽释放酶5和7以及与炎症有关的细胞因子IL-13。它还没有说这种药物可以治疗哪些疾病。第三位候选人正在开发一种遗传性胰腺炎，在美国约有10000人受到影响。

and for which no approved treatments are available.   .

并且没有批准的治疗方法。。

The funding will keep Triveni operating through 2027. Fidelity Management & Research, Deep Track Capital, Cormorant Asset Management and Atlas Venture participated alongside several other firms.

这笔资金将使Triveni运营到2027年。富达管理与研究、Deep Track Capital、Cormorant Asset Management和Atlas Venture与其他几家公司一起参与。

In June, Triveni hired Bhaskar Srivastava, who previously served in senior clinical development roles at Nimbus Therapeutics and Johnson & Johnson, as its chief medical officer.

6月，特里韦尼聘请了Bhaskar Srivastava担任首席医疗官，他之前曾在Nimbus Therapeutics和强生公司担任高级临床开发职务。